Key Takeaways
- Case-by-case evaluation of pending drug-pricing cases almost complete.
- Federal Minister for Economic Affairs directs officials to move cases forward.
- DRAP reviewing existing pricing formula and considering database subscriptions.
The case-by-case evaluation of pending drug-pricing cases in Pakistan is nearing completion, according to a statement from the Ministry of Economic Affairs. Officials briefed the meeting that the evaluation is almost complete.
Federal Minister for Economic Affairs and Establishment Division, Senator Ahad Cheema, chaired a meeting on the Drug Regulatory Authority of Pakistan (DRAP) to review the progress and existing pricing formula. He appreciated the progress and instructed relevant officials to take the cases forward for further processing.
At the meeting, it was noted that the trivalent flu vaccine recommended by the World Health Organisation (WHO) was available in sufficient quantities in the market. DRAP had withdrawn the hardship case concerning the vaccine, as its prices are controlled in the international market.
Senator Cheema also highlighted the need for DRAP to review the existing drug-pricing formula and examine provisions that might hinder the determination of fair and accurate prices. He suggested that DRAP consider purchasing subscriptions to databases specialising in drug pricing to support more independent price assessments.
The minister emphasized that facilitating the public was a top priority and that price increases without valid justification were unacceptable. He observed that comparisons with other countries could provide useful benchmarks, while underscoring the need for independent checks and balances.
Senator Cheema stressed that the pricing formula should be people-centred and should not create unnecessary hurdles for importers or the pharmaceutical sector. He directed DRAP to ensure that the process is transparent and fair.
The meeting concluded with a focus on ensuring that the drug-pricing process is both effective and equitable, with the minister’s emphasis on the importance of public trust and confidence in the system.
Officials are now working to finalize the remaining cases and implement the new pricing formula, aiming to provide better and more accurate drug prices for the public.
